Characteristics | Values (n = 66 patients) |
---|---|
Age at diagnosis (years) | |
Median, range | 51.5, 30–91 |
Stage | |
I | 13 (19.7%) |
II | 39 (59.1%) |
III | 12 (18.2%) |
Undetermined | 2 (3.0%) |
BRCA germline status (Sanger sequencing confirmed) | |
BRCA1 carrier | 5 (7.6%) |
BRCA2 carrier | 2 (3.0%) |
BRCA-negative | 59 (89.4%) |
Progression status | |
PFS | 53 (80.3%) |
Relapse/metastasis | 6 (9.1%) |
Death | 1 (1.5%) |
Undetermined | 6 (9.1%) |
Whether (or not) treated with neoadjuvant therapy | |
Yes | 7 (10.6%) |
No | 55 (83.3%) |
Undetermined | 4 (6.1%) |
Chemotherapy regimen | |
TEC | 16 (24.2%) |
EC-T | 20 (30.3%) |
TC | 3 (4.5%) |
Other | 10 (15.2%) |
None | 17 (25.8%) |